Lilly pays US$415m for rights to ATLX-1282
Building on the January 2025 ALS drug discovery collaboration with Alchemab Therapeutics, Eli Lilly & Company has secured rights to the first IND-ready program under a US$415m licensing agreement.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2071 entries already.
Entries by Thomas Gabrielczyk
Countdown to SLAS Europe: Myxotech GmbH
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: German HIPS spin-out Myxotech GmbH.
Astraveus enters CAR-T cell therapy manufacturing partnership with NecstGen
Astraveus SAS has inked a strategic partnership with NecstGen to evaluate Lakhesys Benchtop Cell Factory for CAR-T therapy manufacturing. Meanwhile, German researchers present a solution to the design of hypoimmunogenic CAR-T cells.
Dynamic42 GmbH starts distribution of organ-on-chip to the US and Canada
Jena-based organ-on-chip specialist Dynamic42 has inked a strategic partnership with Ohio Lumex Co., Inc. The Ohio-based company, which is an established provider of life science and analytics solutions, will exclusively distribute Dynamic42’s human 3D-sphaeroid-based organ-on-chip models in the U.S. and Canadian markets.
Countdown to SLAS Europe: Minos Biosciences SAS
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: French Minos Biosciences SAS.
Countdown to SLAS Europe 2025: Nanoworx BV
Just three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place from 20-22 May in Hamburg, Germany. In a series, European Biotechnology presents the 12 most innovative SMEs. Today: Nanoworx BV.
Countdown to SLAS Europe: Nanovery Ltd.
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: UK-based Nanovery Ltd
betaSense GmbH identifies new diagnostic biomarker for Parkinson’s
A new biomarker for Parkinson’s disease makes it possible to recognise and treat the hereditary dopamine deficiency before the mid-brain is damaged, reports University Bochum spin-out betaSense GmbH.
Oryzon cashes in €30m
Barcelona-based epigentics specialist Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m capital increase through issuing 12,765,958 new shares, priced at €2.35 per share.
Cytovation ASA bags additional US$6m to drive Phase II study
Cytovation ASA has baged US$6m to advance Phase II development of its bi-specific pore-forming peptide candidate CY-101 in patients with adrenocortical carcinoma.